ARID1A Mutations in Gastric Cancer: A Review with Focus on Clinicopathological Features, Molecular Background and Diagnostic Interpretation

Giuseppe Angelico,Giulio Attanasio,Lorenzo Colarossi,Cristina Colarossi,Matteo Montalbano,Eleonora Aiello,Federica Di Vendra,Marzia Mare,Nicolas Orsi,Lorenzo Memeo

DOI: https://doi.org/10.3390/cancers16112062

2024-05-30

Cancers

Abstract:AT-rich interaction domain 1 (ARID1A) is a pivotal gene with a significant role in gastrointestinal tumors which encodes a protein referred to as BAF250a or SMARCF1, an integral component of the SWI/SNF (SWItch/sucrose non-fermentable) chromatin remodeling complex. This complex is instrumental in regulating gene expression by modifying the structure of chromatin to affect the accessibility of DNA. Mutations in ARID1A have been identified in various gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers. These mutations have the potential to disrupt normal SWI/SNF complex function, resulting in aberrant gene expression and potentially contributing to the initiation and progression of these malignancies. ARID1A mutations are relatively common in gastric cancer, particularly in specific adenocarcinoma subtypes. Moreover, such mutations are more frequently observed in specific molecular subtypes, such as microsatellite stable (MSS) cancers and those with a diffuse histological subtype. Understanding the presence and implications of ARID1A mutations in GC is of paramount importance for tailoring personalized treatment strategies and assessing prognosis, particularly given their potential in predicting patient response to novel treatment strategies including immunotherapy, poly(ADP) ribose polymerase (PARP) inhibitors, mammalian target of rapamycin (mTOR) inhibitors, and enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) inhibitors.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the clinicopathological features, molecular background of ARID1A gene mutations in gastric cancer and their impact on diagnosis. Specifically, the paper focuses on the following aspects:

1. **Function of the ARID1A gene and its role in gastric cancer**:
- The ARID1A gene encodes BAF250a or SMARCF1 protein and is an important component of the SWI/SNF chromatin - remodeling complex.
- This complex regulates gene expression by changing chromatin structure, thereby affecting cell function and tumorigenesis.

2. **Frequency and distribution of ARID1A mutations in gastric cancer**:
- ARID1A mutations are relatively common in gastric cancer, especially in some specific adenocarcinoma subtypes.
- The mutation frequency varies in different molecular subtypes, such as being more common in microsatellite - stable (MSS) cancers and the diffuse histological subtype.

3. **Association between ARID1A mutations and the prognosis of gastric cancer**:
- Multiple studies have shown that the loss of ARID1A protein expression is associated with a poor prognosis in gastric cancer patients, including a shortened progression - free survival (PFS) and overall survival (OS).
- However, there are also studies that challenge this view, pointing out that the loss of ARID1A expression may be associated with a better prognosis.

4. **Interaction between ARID1A mutations and other molecular pathways**:
- ARID1A mutations interact with other important genes and signaling pathways such as TP53, PIK3/AKT pathways.
- These interactions may affect tumorigenesis, development and treatment response.

5. **Potential of ARID1A mutations as a treatment target**:
- The paper discusses the potential value of ARID1A mutations in predicting patients' responses to new treatment strategies such as immunotherapy, PARP inhibitors, mTOR inhibitors and EZH2 inhibitors.
- In particular, the relationship between ARID1A mutations and immunotherapy - related biomarkers such as PD - L1 expression, tumor mutation burden (TMB), mismatch repair deficiency (dMMR) and tumor - infiltrating lymphocytes (TILs).

In summary, this paper aims to comprehensively evaluate the significance of ARID1A gene mutations in gastric cancer, especially their potential application in prognosis assessment and personalized treatment strategies.